Jazz Reports Results of Xywav (calcium, magnesium, potassium, and sodium oxybates) in P-III Study for Cataplexy or EDS in Patients with Narcolepsy

October 21, 2020 Auto Bot Clinical Trials, Jazz, narcolepsy, P-III, patients, reports, results, Sleep, Solution, Study 0

Shots:

  • The P-III study involves assessing Xywav vs PBO in patients aged ≥ 7yrs. with cataplexy or EDS with narcolepsy
  • Results: study met its 1EPs & 2EPs i.e. differences in median change in a weekly number of cataplexy attacks and ESS scores. Results were published at World Sleep 2019
  • Xywav is an oxybate product with a unique composition of cations resulting in 92% less sodium or ~1,000- 1,500 mg/night less than sodium oxybate at the recommended dosage range of 6-9gms. The company expects to launch in Q4’20, following RESM implementation

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: GMP News

The post Jazz Reports Results of Xywav (calcium, magnesium, potassium, and sodium oxybates) in P-III Study for Cataplexy or EDS in Patients with Narcolepsy first appeared on PharmaShots.